Life sciences company Revvity (NYSE:RVTY) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 9.3% year on year to $686.9 million. The company’s full-year revenue guidance of $2.83 billion at the midpoint came in 5.2% below analysts’ estimates. Its non-GAAP profit of $1.06 per share was 4.5% above analysts’ consensus estimates.
Is now the time to buy RVTY? Find out in our full research report (it’s free for active Edge members).
Revvity (RVTY) Q1 CY2026 Highlights:
- Revenue: $686.9 million vs analyst estimates of $705.1 million (9.3% year-on-year growth, 2.6% miss)
- Adjusted EPS: $1.06 vs analyst estimates of $1.01 (4.5% beat)
- Adjusted EBITDA: $270.1 million vs analyst estimates of $182.5 million (39.3% margin, 48% beat)
- The company dropped its revenue guidance for the full year to $2.83 billion at the midpoint from $2.98 billion, a 5% decrease
- Management lowered its full-year Adjusted EPS guidance to $5.25 at the midpoint, a 2.8% decrease
- Operating Margin: 11.7%, up from 3.2% in the same quarter last year
- Organic Revenue rose 3% year on year (beat)
- Market Capitalization: $10.32 billion
StockStory’s Take
Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, biotech, and academic institutions. Strong demand for high-content screening and recent software launches also contributed to the quarter’s results.
Looking ahead, Revvity’s updated guidance reflects a more focused business following the planned divestiture of its immunodiagnostics business in China. Management expects this move to enhance growth rates and margins, but also underlines ongoing caution about policy and market uncertainty, especially in China. Singh noted, “We are choosing to concentrate our efforts on business areas where we have clear competitive advantages and see healthy growth trajectories.” The company’s outlook is shaped by continued investment in AI-powered software and operational efficiency programs, as well as expectations for gradual improvement in customer spending across core markets.
Key Insights from Management’s Remarks
Management credited the quarter’s outperformance to operational discipline, the decision to exit a challenged Chinese diagnostics market, and expanded software offerings targeting drug discovery and development.
- China immunodiagnostics divestiture: Revvity announced a strategic plan to divest its immunodiagnostics business in China, citing persistent policy headwinds and low returns. Management expects this move to improve organic growth rates and operating margins while freeing up capital for higher-value initiatives. The business represented about 6% of total revenue last year.
- Life Sciences resilience: The Life Sciences segment, particularly reagents and instruments, showed renewed growth. Management pointed to strong demand from pharma and biotech customers, as well as improving trends in academic and government funding, which resulted in the segment’s best year-over-year growth for this group since early 2023.
- Software innovation momentum: Revvity launched several new software products, including BioDesign and Xynthetica, which leverage artificial intelligence to accelerate drug discovery workflows. Management highlighted the Lilly TuneLab partnership as an example of growing demand and engagement in its SaaS pipeline, with annual recurring revenue growth of 40%.
- Reproductive health strength: The Diagnostics segment benefited from double-digit organic growth in reproductive health, driven by continued success in newborn screening and contributions from the Genomics England contract. This business outpaced global birth rate trends, supported by geographic expansion and new assay development.
- Operational efficiency initiatives: The company continued executing on cost efficiency programs, particularly through organizational streamlining and technology-enabled productivity improvements. Management expects these actions to drive a step-up in operating margins, especially in the second half of the year and into 2027.
Drivers of Future Performance
Revvity’s guidance is driven by a streamlined portfolio, ongoing cost initiatives, and accelerating investment in AI-powered research tools.
- Portfolio optimization impact: The divestiture of the China immunodiagnostics unit is expected to enhance organic growth and margin profiles, with management projecting a 100 basis point improvement in annual organic growth and a 30 basis point lift in operating margins. This move also reduces exposure to volatile policy environments.
- AI and software-driven growth: Management anticipates that demand for AI-enabled software and advanced instruments will rise as pharmaceutical and biotech customers increase their investments in drug discovery and validation. New product launches, such as BioDesign and LabGistics, are intended to capture this emerging demand.
- Operational efficiency and cost control: Ongoing cost reduction efforts, including delayering management and optimizing supply chains, are expected to deliver additional margin expansion. Management believes these initiatives will be fully realized by midyear, with further benefits annualizing into 2027.
Catalysts in Upcoming Quarters
Over the next few quarters, the StockStory team will be monitoring (1) progress toward closing the China immunodiagnostics divestiture and its impact on reported financials, (2) adoption rates for new AI-driven software and instrument launches, and (3) evidence of sustained recovery in pharma, biotech, and academic customer demand. Execution on operational efficiency programs and further updates on capital deployment will also be closely watched.
Revvity currently trades at $97.76, up from $86.51 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.